The vaccine being developed by Hyderabad-based Bharat Biotech

The vaccine being developed by Hyderabad-based Bharat Biotech, in collaboration with the National Institute of Virology (NIV), Pune, COVAXIN has entered into the crucial phase of human trials with the first dose being administered to two volunteers at the Nizam’s Institute of Medical Sciences here on Monday.

“We gave the first dosage of the vaccine to two volunteers. Both of them are healthy and under observation,” said Dr Prabhakar, Assistant Director, NIMS.

This is randomised, double-blind, placebo-controlled clinical trial in India. A total of 12 medical centres across the country are involved in Phase-1 clinical trials of the vaccine. Earlier this month, the DCGI has approved the vaccine for human clinical trial.

This is the first vaccine developed in India and got permission for human trial. Many countries are in the race of developing the vaccine. AstraZeneca, the pharma company developing vaccine under the supervision of Oxford University, is in the lead in the competition as they have already entered the third stage of human trials.

Also, earlier this month, the ICMR said they will release the vaccine for the public on August 15.

Leave a Reply

Your email address will not be published. Required fields are marked *